Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Prostate Cancer

  Free Subscription

Articles published in BJU Int

Retrieve available abstracts of 391 articles:
HTML format

Single Articles

    November 2020
  1. EGEVAD L, Delahunt B, Bostwick DG, Cheng L, et al
    Prostate Cancer Grading, Time To Go Back To the Future.
    BJU Int. 2020 Nov 18. doi: 10.1111/bju.15298.
    PubMed     Abstract available

  2. NORRIS JM, Carmona Echeverria LM, Simpson BS, Ball R, et al
    Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out.
    BJU Int. 2020 Nov 13. doi: 10.1111/bju.15295.
    PubMed     Abstract available

  3. POULSON M, Helrich S, Kenzik K, Dechert T, et al
    The Impact of Residential Segregation on Prostate Cancer Diagnosis and Treatment.
    BJU Int. 2020 Nov 9. doi: 10.1111/bju.15293.
    PubMed     Abstract available

    October 2020
  4. SCHOOTS IG, Padhani AR
    Risk-adapted biopsy decision based on prostate MRI and PSA-density for enhanced biopsy avoidance in first prostate cancer diagnostic work-up.
    BJU Int. 2020 Oct 21. doi: 10.1111/bju.15277.
    PubMed     Abstract available

  5. FUJIHARA A, Iwata T, Shakir A, Tafuri A, et al
    Multiparametric Magnetic Resonance Imaging Facilitates Reclassification During Active Surveillance for Prostate Cancer.
    BJU Int. 2020 Oct 11. doi: 10.1111/bju.15272.
    PubMed     Abstract available

  6. EXTERKATE L, Peters M, Somford DM, Vergunst H, et al
    Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer.
    BJU Int. 2020 Oct 11. doi: 10.1111/bju.15269.
    PubMed     Abstract available

  7. NAIR SM, Hatiboglu G, Relle J, Hetou K, et al
    MRI-Guided Transurethral Ultrasound Ablation in Patients with Localized Prostate Cancer: Three Year Outcomes of a Prospective Phase I Study.
    BJU Int. 2020 Oct 9. doi: 10.1111/bju.15268.
    PubMed     Abstract available

  8. WHISH-WILSON T, Costello D, Finch S, Sutherland T, et al
    Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer.
    BJU Int. 2020 Oct 6. doi: 10.1111/bju.15231.
    PubMed     Abstract available

    September 2020
  9. STROMAN L, Cathcart P, Lamb A, Challacombe B, et al
    A cross-section of UK prostate cancer diagnostics during the COVID-19 era - a shifting paradigm?
    BJU Int. 2020 Sep 27. doi: 10.1111/bju.15259.
    PubMed     Abstract available

  10. DIAO W, Cao Y, Su D, Jia Z, et al
    (68) Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence.
    BJU Int. 2020 Sep 26. doi: 10.1111/bju.15257.
    PubMed     Abstract available

  11. MADAN RA, Karzai FH, Al Harthy M, Petrylak DP, et al
    Cabozantinib plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
    BJU Int. 2020 Sep 24. doi: 10.1111/bju.15227.
    PubMed     Abstract available

  12. MARVASO G, Montesano M, Corrao G, De Angelis SP, et al
    Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?
    BJU Int. 2020 Sep 24. doi: 10.1111/bju.15228.
    PubMed     Abstract available

  13. GOLDBERG H, Glicksman R, Woon D, Hoffman A, et al
    Can postreatment free psa ratio be used to predict adverse outcomes in recurrent prostate cancer?
    BJU Int. 2020 Sep 14. doi: 10.1111/bju.15236.
    PubMed     Abstract available

  14. ODERDA M, Diamand R, Albisinni S, Calleris G, et al
    Indications and complications of pelvic lymph node dissection for prostate cancer: are currently available nomograms accurate to predict lymph node invasion?
    BJU Int. 2020 Sep 1. doi: 10.1111/bju.15220.
    PubMed     Abstract available

  15. CAHILL D
    How the Martini-Klinik handled prostate surgery during COVID-19.
    BJU Int. 2020;126:E1.

    July 2020
    Prostate cancer screening and treatment: where have we come from and where are we going?
    BJU Int. 2020 Jul 27. doi: 10.1111/bju.15153.
    PubMed     Abstract available

  17. UCHIMOTO T, Komura K, Fukuokaya W, Kimura T, et al
    Risk Stratification for the Prediction of Overall Survival Could Assists Treatment Decision Making at the Diagnosis of Castration-Resistant Prostate Cancer - a Multicenter Collaborative Study in Japan.
    BJU Int. 2020 Jul 23. doi: 10.1111/bju.15187.
    PubMed     Abstract available

  18. DUNN J, Green A, Ralph N, Newton RU, et al
    Prostate Cancer Survivorship Essentials Framework: Guidelines for Practitioners.
    BJU Int. 2020 Jul 5. doi: 10.1111/bju.15159.
    PubMed     Abstract available

    June 2020
  19. MATTI B, Lyndon M, Zargar-Shoshtari K
    Ethnic and Socioeconomic disparities in Prostate Cancer Screening - Lessons from New Zealand.
    BJU Int. 2020 Jun 29. doi: 10.1111/bju.15155.
    PubMed     Abstract available

  20. CHEN MY, Franklin A, Yaxley J, Gianduzzo T, et al
    Solitary rib lesions showing PSMA uptake in pre-treatment staging (68) Ga-PSMA-11 PET scans for men with prostate cancer: benign or malignant?
    BJU Int. 2020 Jun 27. doi: 10.1111/bju.15152.
    PubMed     Abstract available

  21. ANTON A, Kamel Hasan O, Ballok Z, Bowden P, et al
    Use of PSMA PET/CT in Response Assessment Following Upfront Chemohormonal Therapy in Metastatic Prostate Cancer.
    BJU Int. 2020 Jun 24. doi: 10.1111/bju.15151.
    PubMed     Abstract available

  22. MAYOR N, Sathianathen NJ, Buteau J, Koschel S, et al
    PSMA Theranostics in advanced prostate cancer: an evolving option.
    BJU Int. 2020 Jun 19. doi: 10.1111/bju.15143.
    PubMed     Abstract available

  23. TOMER A, Nieboer D, Roobol MJ, Bjartell A, et al
    Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15136.
    PubMed     Abstract available

  24. PFISTER D, Haidl F, Nestler T, Verburg F, et al
    (68) Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15135.
    PubMed     Abstract available

  25. FRANKLIN A, Yaxley WJ, Raveenthiran S, Coughlin G, et al
    Histological comparison between predictive value of pre-operative 3T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15134.
    PubMed     Abstract available

  26. AKAKURA K, Bolton D, Grillo V, Mermod N, et al
    Not All Prostate Cancer is the Same - Patient perceptions: An Asia-Pacific study.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15129.
    PubMed     Abstract available

    Low-dose-rate brachytherapy for prostate cancer stands the test of time - the Swiss experience.
    BJU Int. 2020;125:750-751.

  28. SEETHARAM BHAT KR, Moschovas MC, Onol FF, Sandri M, et al
    Trends in clinical and oncological outcomes of robot-assisted radical prostatectomy before and after the 2012 US Preventive Services Task Force recommendation against PSA screening: a decade of experience.
    BJU Int. 2020;125:884-892.
    PubMed     Abstract available

    May 2020
  29. MARRA G, Zhuang J, Beltrami M, Calleris G, et al
    Transperineal free-hand mpMRI fusion targeted biopsies under local anesthesia for Prostate Cancer Diagnosis: a multicenter prospective study of 1,014 cases.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15121.
    PubMed     Abstract available

  30. POPERT R, Kum F, MacAskill F, Stroman L, et al
    Our First Month of Delivering the Prostate Cancer Diagnostic Pathway within the Limitations of COVID-19 Using Local Anaesthetic Transperineal Biopsy.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15120.
    PubMed     Abstract available

  31. WURNSCHIMMEL C, Maurer T, Knipper S, von Breunig F, et al
    Martini-Klinik experience on prostate cancer surgery during the early phase of COVID-19.
    BJU Int. 2020 May 18. doi: 10.1111/bju.15115.
    PubMed     Abstract available

  32. JOSHI A, Roberts MJ, Alinezhad S, Williams ED, et al
    Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
    BJU Int. 2020 May 8. doi: 10.1111/bju.15103.
    PubMed     Abstract available

  33. SCHWEN ZR, Mamawala M, Tosoian JJ, Druskin SC, et al
    Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance.
    BJU Int. 2020 May 4. doi: 10.1111/bju.15101.
    PubMed     Abstract available

  34. SHAPIRO DD, Ward JF, Lim AH, Nogueras-Gonzalez GM, et al
    Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.
    BJU Int. 2020 May 1. doi: 10.1111/bju.15100.
    PubMed     Abstract available

  35. HAEUSER L, Nguyen DD, Trinh QD
    Prostate cancer and kidney transplantation - exclusion or co-existence?
    BJU Int. 2020;125:628-629.

  36. NABI J
    The provision of comfort: addressing barriers to sleep in prostate cancer.
    BJU Int. 2020;125:627-628.

  37. SIGHINOLFI MC, Eissa A, Spandri V, Puliatti S, et al
    Positive surgical margin during radical prostatectomy: overview of sampling methods for frozen sections and techniques for the secondary resection of the neurovascular bundles.
    BJU Int. 2020;125:656-663.
    PubMed     Abstract available

  38. YAMAMOTO A, Kato M, Hattori K, Naito Y, et al
    Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
    BJU Int. 2020;125:702-708.
    PubMed     Abstract available

    April 2020
  39. SEYMOUR ZA, Hamstra DA, Daignault-Newton S, Bosch W, et al
    Long-term Follow-up After Radiotherapy for Prostate Cancer with and without Rectal Hydrogel Spacer: A Pooled Prospective Evaluation of Bowel Associated Quality of Life.
    BJU Int. 2020 Apr 25. doi: 10.1111/bju.15097.
    PubMed     Abstract available

  40. HEIDENREICH A, Bludau M, Bruns C, Nestler T, et al
    Pelvic exenteration surgery in patients with locally advanced castration-naive and castration-resistant, symptomatic prostate cancer.
    BJU Int. 2020 Apr 22. doi: 10.1111/bju.15088.
    PubMed     Abstract available

  41. NORRIS JM, Carmona Echeverria LM, Simpson BS, Allen C, et al
    Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: High Gleason Grade and Increased Tumour Volume are Not the Only Important Histopathological Features.
    BJU Int. 2020 Apr 22. doi: 10.1111/bju.15085.
    PubMed     Abstract available

  42. MANNAERTS CK, Engelbrecht MRW, Postema AW, van Kollenburg RAA, et al
    Detection of clinically significant prostate cancer in biopsy-naive men: Head-to-head comparison of systematic biopsy, multiparametric MRI- and contrast ultrasound dispersion imaging-targeted biopsy.
    BJU Int. 2020 Apr 21. doi: 10.1111/bju.15093.
    PubMed     Abstract available

  43. SZARVAS T, Csizmarik A, Fazekas T, Huttl A, et al
    Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    BJU Int. 2020 Apr 20. doi: 10.1111/bju.15086.
    PubMed     Abstract available

  44. BORNO HT, Zhang S, Bakke B, Bell A, et al
    Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.
    BJU Int. 2020 Apr 10. doi: 10.1111/bju.15081.
    PubMed     Abstract available

  45. ORRASON AW, Westerberg M, Garmo H, Franck Lissbrant I, et al
    Changes in treatment and mortality in men with locally advanced prostate cancer between 2000-2016. Nationwide, population-based study in Sweden.
    BJU Int. 2020 Apr 10. doi: 10.1111/bju.15077.
    PubMed     Abstract available

    Estimating the threat posed by prostate cancer.
    BJU Int. 2020;125:480-481.

  47. STONIER T, Cathcart P
    Further evidence that surgery after focal therapy for prostate cancer is safe.
    BJU Int. 2020;125:481-482.

  48. TUGCU V, Eksi M, Sahin S, Colakoglu Y, et al
    Robot-assisted radical perineal prostatectomy: a review of 95 cases.
    BJU Int. 2020;125:573-578.
    PubMed     Abstract available

  49. ROCCO B, Sighinolfi MC, Bertoni L, Spandri V, et al
    Real-time assessment of surgical margins during radical prostatectomy: a novel approach that uses fluorescence confocal microscopy for the evaluation of peri-prostatic soft tissue.
    BJU Int. 2020;125:487-489.

  50. BRYANT RJ, Oxley J, Young GJ, Lane JA, et al
    The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
    BJU Int. 2020;125:506-514.
    PubMed     Abstract available

  51. HERRERA-CACERES JO, Nason GJ, Salgado-Sanmamed N, Goldberg H, et al
    Salvage radical prostatectomy following focal therapy: functional and oncological outcomes.
    BJU Int. 2020;125:525-530.
    PubMed     Abstract available

  52. WAJSWOL E, Winoker JS, Anastos H, Falagario U, et al
    A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
    BJU Int. 2020;125:531-540.
    PubMed     Abstract available

    March 2020
  53. OSSES DF, Drost FH, Verbeek JFM, Luiting HB, et al
    Prostate cancer upgrading with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    BJU Int. 2020 Mar 31. doi: 10.1111/bju.15065.
    PubMed     Abstract available

  54. HUITS TH, Luiting HB, van der Poel H, Nandurkar R, et al
    The distribution of prostate cancer recurrences on (68) Ga-PSMA PET/CT after radical prostatectomy with pathological node positive extended lymph node dissection.
    BJU Int. 2020 Mar 17. doi: 10.1111/bju.15052.
    PubMed     Abstract available

  55. RANASINGHE W, Chapin BF, Kim IY, Sooriakumaran P, et al
    The Cytoreductive prostatectomy in Metastatic Prostate Cancer: What the individual trials are hoping to answer.
    BJU Int. 2020 Mar 16. doi: 10.1111/bju.15055.
    PubMed     Abstract available

  56. LUZZAGO S, de Cobelli O, Cozzi G, Peveri G, et al
    A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    BJU Int. 2020 Mar 9. doi: 10.1111/bju.15048.
    PubMed     Abstract available

  57. DONG L, Zhang Z, Smith K, Kuczler M, et al
    The combination of size-based separation and selection-free technology provides higher circulating tumor cells detection sensitivity than either method alone in patients with metastatic prostate cancer.
    BJU Int. 2020 Mar 1. doi: 10.1111/bju.15041.
    PubMed     Abstract available

  58. TEOH JY, Chiong E, Ng CF
    Can artificial intelligence optimize case selection for hemi-gland ablation?
    BJU Int. 2020;125:333-334.

  59. GLASER ZA, Rais-Bahrami S
    Magnetic resonance imaging as a personalised tool to safely avoid prostate biopsy.
    BJU Int. 2020;125:335-336.

  60. FRANCOLINI G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, et al
    Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series.
    BJU Int. 2020;125:417-425.
    PubMed     Abstract available

    February 2020
  61. MORTEZAVI A, Eklund M, Bergman M, Kjosavik SR, et al
    Association between PSA density and prostate cancer in men without significant MRI lesions.
    BJU Int. 2020 Feb 28. doi: 10.1111/bju.15037.
    PubMed     Abstract available

  62. SOOD A, Keeley J, Palma-Zamora I, Dalela D, et al
    Extended pelvic lymph-node dissection is independently associated with improved overall survival in prostate cancer patients at high-risk for lymph-node invasion.
    BJU Int. 2020 Feb 11. doi: 10.1111/bju.15034.
    PubMed     Abstract available

  63. MAMAWALA MK, Meyer A, Landis P, Macura KJ, et al
    Utility of multiparametric MRI in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
    BJU Int. 2020 Feb 10. doi: 10.1111/bju.15033.
    PubMed     Abstract available

  64. ALLOTT EH, Csizmadi I, Howard LE, Muller RL, et al
    Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    BJU Int. 2020;125:226-233.
    PubMed     Abstract available

  65. HANSEN NL, Barrett T, Lloyd T, Warren A, et al
    Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy.
    BJU Int. 2020;125:260-269.
    PubMed     Abstract available

  66. SAAD M, Moschini M, Stabile A, Macek P, et al
    Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience.
    BJU Int. 2020;125:253-259.
    PubMed     Abstract available

  67. KUM F, Elhage O, Maliyil J, Wong K, et al
    Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting.
    BJU Int. 2020;125:244-252.
    PubMed     Abstract available

    January 2020
  68. LOVEGROVE CE, Peters M, Guillaumier S, Arya M, et al
    Evaluation of functional outcomes following a second focal-HIFU in men with primary localised, non-metastatic prostate cancer; Results from the High Intensity Focused Ultrasound Evaluation and Assessment of Treatment (HEAT) Registry.
    BJU Int. 2020 Jan 23. doi: 10.1111/bju.15004.
    PubMed     Abstract available

  69. VIKTORIN P, Putora PM, Schmid HP, Plasswilm L, et al
    Long-term oncological and functional follow-up in low dose rate brachytherapy (LDR-BT) for prostate cancer: results from the prospective nation-wide Swiss Registry.
    BJU Int. 2020 Jan 21. doi: 10.1111/bju.15003.
    PubMed     Abstract available

  70. AMIN A, Blazevski A, Thompson J, Scheltema MJ, et al
    PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prost
    BJU Int. 2020 Jan 19. doi: 10.1111/bju.14999.
    PubMed     Abstract available

  71. BRATT O, Drevin L, Prutz KG, Carlsson S, et al
    Prostate cancer in kidney transplant recipients- a nationwide register study.
    BJU Int. 2020 Jan 19. doi: 10.1111/bju.15002.
    PubMed     Abstract available

  72. LOVEGROVE CE, Musbahi O, Ranasinha N, Omer A, et al
    Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit- The "Fry-Turnbull" Effect.
    BJU Int. 2020 Jan 7. doi: 10.1111/bju.14992.
    PubMed     Abstract available

  73. ROBBINS R, Jean-Louis G, Chanko N, Combs P, et al
    Using data from an online health community to examine the impact of prostate cancer on sleep.
    BJU Int. 2020 Jan 3. doi: 10.1111/bju.14986.
    PubMed     Abstract available

  74. JAMBOR I, Falagario U
    Does prostate magnetic resonance imaging (MRI) reporting system affect performance of MRI in men with a clinical suspicion of prostate cancer?
    BJU Int. 2020;125:4-5.

  75. ONOL FF, Bhat S, Moschovas M, Rogers T, et al
    Comparison of outcomes of salvage robot-assisted laparoscopic prostatectomy for post-primary radiation vs focal therapy.
    BJU Int. 2020;125:103-111.
    PubMed     Abstract available

  76. KHAN-RUF S, Thurairajah R, Khan MS, Bultitude M, et al
    Digging through a genomic goldmine: defining the optimum upper urinary tract surveillance strategy for Lynch syndrome.
    BJU Int. 2020;125:6-7.

    December 2019
  77. UEMURA H, Ye D, Kanesvaran R, Chiong E, et al
    United in Fight against prOstate cancer registry (UFO): first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia.
    BJU Int. 2019 Dec 23. doi: 10.1111/bju.14980.
    PubMed     Abstract available

    November 2019
  78. WOLLERSHEIM BM, Boekhout AH, van der Poel HG, van de Poll-Franse LV, et al
    The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression.
    BJU Int. 2019 Nov 26. doi: 10.1111/bju.14961.
    PubMed     Abstract available

    Evaluating psychological support services available for men living with prostate cancer and their carers and families across England.
    BJU Int. 2019 Nov 26. doi: 10.1111/bju.14959.
    PubMed     Abstract available

  80. PULLEN L, Radtke JP, Wiesenfarth M, Roobol MJ, et al
    External validation of novel MRI-based models for prostate cancer prediction.
    BJU Int. 2019 Nov 23. doi: 10.1111/bju.14958.
    PubMed     Abstract available

  81. ELDRED-EVANS D, Neves JB, Simmons LAM, Kanthabalan A, et al
    The added value of diffusion-weighted images and dynamic contrast-enhancement in multi-parametric MRI for the detection of clinically significant prostate cancer in the PICTURE trial.
    BJU Int. 2019 Nov 16. doi: 10.1111/bju.14953.
    PubMed     Abstract available

  82. BLAZEVSKI A, Scheltema MJ, Amin A, Thompson J, et al
    Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    BJU Int. 2019 Nov 14. doi: 10.1111/bju.14951.
    PubMed     Abstract available

  83. LANGLEY S, Uribe J, Uribe-Lewis S, Franklin A, et al
    Hemi-Ablative Low-Dose-Rate Prostate Brachytherapy for Unilateral Localised Prostate Cancer.
    BJU Int. 2019 Nov 9. doi: 10.1111/bju.14948.
    PubMed     Abstract available

  84. ZHOU SR, Priester AM, Jayadevan R, Johnson DC, et al
    Using Spatial Tracking with MRI/Ultrasound-Guided Biopsy to Identify Unilateral Prostate Cancer.
    BJU Int. 2019 Nov 4. doi: 10.1111/bju.14943.
    PubMed     Abstract available

  85. LUITING HB, van Leeuwen PJ, Busstra MB, Brabander T, et al
    Use of (68) Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    BJU Int. 2019 Nov 4. doi: 10.1111/bju.14944.
    PubMed     Abstract available

    October 2019
  86. THANGASAMY IA, Kwan EM, Teh J, Sathianathen N, et al
    Novel agents for metastatic hormone-sensitive prostate cancer - A practice guide for urologists.
    BJU Int. 2019 Oct 29. doi: 10.1111/bju.14936.
    PubMed     Abstract available

  87. KLOTZ L
    Active surveillance in intermediate risk prostate cancer.
    BJU Int. 2019 Oct 24. doi: 10.1111/bju.14935.
    PubMed     Abstract available

  88. HOFMAN MS, Emmett L, Violet J, Y Zhang A, et al
    TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
    BJU Int. 2019 Oct 22. doi: 10.1111/bju.14876.
    PubMed     Abstract available

  89. MACIAS VA, Barrera-Mellado I
    Ultra-Hypofractionated Radiation Therapy for Unfavorable Intermediate-Risk and High-Risk Prostate Cancer is Safe and Effective: 5-year Outcomes of a Phase II Trial.
    BJU Int. 2019 Oct 15. doi: 10.1111/bju.14925.
    PubMed     Abstract available

  90. NDJAVERA W, Orange ST, O'Doherty AF, Leicht AS, et al
    Exercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation therapy: a randomised controlled trial.
    BJU Int. 2019 Oct 12. doi: 10.1111/bju.14922.
    PubMed     Abstract available

  91. NORRIS JM, Simpson BS, Parry MA, Kasivisvanathan V, et al
    Genetic correlates of prostate cancer visibility (and invisibility) on mpMRI: It's time to take stock.
    BJU Int. 2019 Oct 10. doi: 10.1111/bju.14919.
    PubMed     Abstract available

  92. KHOO CC, Eldred-Evans D, Peters M, Bertoncelli Tanaka M, et al
    Likert vs. PI-RADS v2: A Comparison of Two Radiological Scoring Systems for Detection of Clinically Significant Prostate Cancer.
    BJU Int. 2019 Oct 9. doi: 10.1111/bju.14916.
    PubMed     Abstract available

    September 2019
    Informing informed decision making in Primary Prostate Cancer treatment selection.
    BJU Int. 2019 Sep 12. doi: 10.1111/bju.14910.
    PubMed     Abstract available

  94. ONG WL, Koh TL, Lim Joon D, Chao M, et al
    Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literatur
    BJU Int. 2019 Sep 11. doi: 10.1111/bju.14886.
    PubMed     Abstract available

  95. ROBERTS MJ, Papa N, Perera M, Scott S, et al
    A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer.
    BJU Int. 2019 Sep 5. doi: 10.1111/bju.14773.
    PubMed     Abstract available

  96. COOK GJR, Kulkarni M, Warbey VS
    PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer.
    BJU Int. 2019;124:357-358.

    August 2019
  97. SALTER CA, Mulhall JP
    Guideline of Guidelines: Testosterone Replacement Therapy for Testosterone Deficiency.
    BJU Int. 2019 Aug 17. doi: 10.1111/bju.14899.
    PubMed     Abstract available

  98. HOU Y, Bao ML, Wu CJ, Zhang J, et al
    A Machine Learning-assisted Decision Support Model Can Better Spare Extended Pelvic Lymph Node Dissection in Prostate Cancer.
    BJU Int. 2019 Aug 7. doi: 10.1111/bju.14892.
    PubMed     Abstract available

  99. SAKELLARIOU C, Elhage O, Papaevangelou E, Giustarini G, et al
    Prostate cancer cells enhance IL-15-mediated expansion of NK cells.
    BJU Int. 2019 Aug 7. doi: 10.1111/bju.14893.
    PubMed     Abstract available

    Dropping the GAD - just a fad? The case for a simpler, quicker, safer and cheaper prostate magnetic resonance imaging.
    BJU Int. 2019;124:183-184.

  101. FERRONI MC, Abaza R
    Feasibility of robot-assisted prostatectomy performed at ultra-low pneumoperitoneum pressure of 6 mmHg and comparison of clinical outcomes vs standard pressure of 15 mmHg.
    BJU Int. 2019;124:308-313.
    PubMed     Abstract available

    July 2019
  102. BENARD A, Duroux T, Robert G
    Cost-utility analysis of focal HIFU versus active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state Model.
    BJU Int. 2019 Jul 12. doi: 10.1111/bju.14867.
    PubMed     Abstract available

  103. SCHELTEMA MJ, Chang JI, Stricker PD, van Leeuwen PJ, et al
    Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of
    BJU Int. 2019 Jul 9. doi: 10.1111/bju.14794.
    PubMed     Abstract available

  104. MEYER AR, Rowe SP, Gorin MA
    Preoperative PSMA-targeted PET imaging: more than just a tool for prostate cancer staging?
    BJU Int. 2019;124:2-3.

  105. DASGUPTA P, Davis J, Hughes S
    NICE guidelines on prostate cancer 2019.
    BJU Int. 2019;124:1.

  106. WATSON RW, Taltsh O
    Transcriptomic signatures for tertiary pattern 5 in prostate cancer.
    BJU Int. 2019;124:4-5.

  107. NICE Guidance - Prostate cancer: diagnosis and management: (c) NICE (2019) Prostate cancer: diagnosis and management.
    BJU Int. 2019;124:9-26.

  108. KALAPARA AA, Nzenza T, Pan HY, Ballok Z, et al
    Detection and localisation of primary prostate cancer using (68) Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.
    BJU Int. 2019 Jul 1. doi: 10.1111/bju.14858.
    PubMed     Abstract available

  109. MARTINI A, Wang J, Brown NM, Cumarasamy S, et al
    A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome.
    BJU Int. 2019;124:155-162.
    PubMed     Abstract available

  110. MARTINI A, Cumarasamy S, Haines KG III, Tewari AK, et al
    An updated approach to incremental nerve sparing for robot-assisted radical prostatectomy.
    BJU Int. 2019;124:103-108.
    PubMed     Abstract available

  111. FREEDLAND SJ, Branche BL, Howard LE, Hamilton RJ, et al
    Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
    BJU Int. 2019;124:69-75.
    PubMed     Abstract available

    June 2019
  112. REZAEE ME, Goddard B, Sverrisson EF, Seigne JD, et al
    Dr. Google: Trends in Online Interest in Prostate Cancer Screening, Diagnosis and Treatment.
    BJU Int. 2019 Jun 17. doi: 10.1111/bju.14846.
    PubMed     Abstract available

  113. HAESE A, Knipper S, Isbarn H, Heinzer H, et al
    A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.
    BJU Int. 2019;123:1031-1040.
    PubMed     Abstract available

  114. REYNOLDS HM, Williams S, Jackson P, Mitchell C, et al
    Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    BJU Int. 2019;123:1020-1030.
    PubMed     Abstract available

    May 2019
  115. HOSTIOU T, Gelet A, Chapelon JY, Rouviere O, et al
    Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncologic and functional outcomes.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14838.
    PubMed     Abstract available

  116. MAZZONE E, Mistretta FA, Knipper S, Palumbo C, et al
    Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14841.
    PubMed     Abstract available

  117. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samaratunga H, et al
    Risk of metastatic disease on (68) Ga-PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    BJU Int. 2019 May 29. doi: 10.1111/bju.14828.
    PubMed     Abstract available

  118. MURPHY DG, Hofman MS, Azad A, Violet J, et al
    Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.
    BJU Int. 2019 May 24. doi: 10.1111/bju.14814.
    PubMed     Abstract available

  119. CONNELL SP, Hanna M, McCarthy F, Hurst R, et al
    A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.
    BJU Int. 2019 May 20. doi: 10.1111/bju.14811.
    PubMed     Abstract available

  120. TONTTILA PP, Ahtikoski A, Kuisma M, Paakko E, et al
    Multiparametric magnetic resonance imaging prior to radical prostatectomy identifies intraductal and cribriform growth pattern of prostate cancer.
    BJU Int. 2019 May 18. doi: 10.1111/bju.14812.
    PubMed     Abstract available

  121. QU LG, Wardan H, Davis ID, Iddawela M, et al
    Circulating Estrogen Receptor Mutations and Splice Variants in Advanced Prostate Cancer.
    BJU Int. 2019 May 15. doi: 10.1111/bju.14797.
    PubMed     Abstract available

  122. SAAD M, Alip A, Lim J, Abdullah MM, et al
    Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14807.
    PubMed     Abstract available

  123. GNANAPRAGASAM VJ, Barrett T, Thankapannair V, Thurtle D, et al
    Using prognosis to guide inclusion criteria, define standardized end-points and stratify follow up in active surveillance for prostate cancer.
    BJU Int. 2019 May 7. doi: 10.1111/bju.14800.
    PubMed     Abstract available

  124. REMMERS S, Verbeek JFM, Nieboer D, van der Kwast T, et al
    Predicting biochemical recurrence and prostate cancer specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of screen and clinically detected prostate cancer patients.
    BJU Int. 2019 May 4. doi: 10.1111/bju.14790.
    PubMed     Abstract available

  125. FINE ND, LaPolla F, Epstein M, Loeb S, et al
    Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.
    BJU Int. 2019 May 4. doi: 10.1111/bju.14799.
    PubMed     Abstract available

  126. DEL RE M, Crucitta S, Sbrana A, Rofi E, et al
    AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.
    BJU Int. 2019 May 4. doi: 10.1111/bju.14792.
    PubMed     Abstract available

  127. HERLEMANN A, Meng MV
    Editorial: Conversion to negative surgical margin after intraoperative frozen section - (un)necessary effort and relevance in 2019?
    BJU Int. 2019;123:744-746.

  128. AHN T, Roberts MJ, Strahan A, Malone G, et al
    Improved lower urinary tract symptoms after robot-assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling.
    BJU Int. 2019;123 Suppl 5:47-53.
    PubMed     Abstract available

  129. SEWELL J, Chow K, De Sousa A, Sapre N, et al
    Extended-spectrum beta-lactamase in the rectal flora of patients undergoing transrectal prostate biopsy: a study of the prevalence in a major metropolitan hospital.
    BJU Int. 2019;123 Suppl 5:43-46.
    PubMed     Abstract available

  130. SLUKA P, Pezaro C, Wardan H, Sengupta S, et al
    Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and non-malignant prostate epithelial cells.
    BJU Int. 2019;123 Suppl 5:27-35.
    PubMed     Abstract available

    April 2019
  131. RANASINGHE WKB, Williams S, Ischia J, Wetherell D, et al
    Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
    BJU Int. 2019 Apr 23. doi: 10.1111/bju.14709.
    PubMed     Abstract available

  132. VILLUMSEN BR, Jorgensen MG, Frystyk J, Hordam B, et al
    Home-based exergaming was safe and significantly improved 6-min walking distance in prostate cancer patients: a single-blinded randomized controlled trial.
    BJU Int. 2019 Apr 22. doi: 10.1111/bju.14782.
    PubMed     Abstract available

  133. REICHARD CA, Hoffman KE, Tang C, Williams SB, et al
    Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment.
    BJU Int. 2019 Apr 22. doi: 10.1111/bju.14780.
    PubMed     Abstract available

  134. SARGOS P, Mottet N, Bellera C, Richaud P, et al
    Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: updated results from a phase III randomized trial.
    BJU Int. 2019 Apr 4. doi: 10.1111/bju.14768.
    PubMed     Abstract available

    The burden of urological cancers in low- and middle-income countries.
    BJU Int. 2019;123:557.

    March 2019
  136. ALABOUSI M, Salameh JP, Gusenbauer K, Samoilov L, et al
    Biparametric versus Multiparametric Prostate MRI for the Detection of Prostate Cancer in Treatment-Naive Patients: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis.
    BJU Int. 2019 Mar 31. doi: 10.1111/bju.14759.
    PubMed     Abstract available

  137. SZYMANIAK JA, Mata DA, Cole AP
    Are historical studies relevant in the setting of grade migration?
    BJU Int. 2019;123:375-376.

  138. PRESS B, Rosenkrantz AB, Huang R, Taneja SS, et al
    The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI-ultrasound fusion-targeted biopsy.
    BJU Int. 2019;123:439-446.
    PubMed     Abstract available

  139. PORPIGLIA F, Manfredi M, Checcucci E, Garrou D, et al
    Use of chitosan membranes after nerve-sparing radical prostatectomy improves early recovery of sexual potency: results of a comparative study.
    BJU Int. 2019;123:465-473.
    PubMed     Abstract available

  140. GALLAGHER KM, Christopher E, Cameron AJ, Little S, et al
    Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
    BJU Int. 2019;123:429-438.
    PubMed     Abstract available

    February 2019
  141. KE Y, Taylor J, Gao LL, Wang H, et al
    Twitter Response to the 2018 United States Preventive Services Task Force Guidelines on Prostate Cancer Screening.
    BJU Int. 2019 Feb 27. doi: 10.1111/bju.14734.
    PubMed     Abstract available

  142. LOPCI E, Piccardo A, Lazzeri M
    Prostate cancer imaging and therapeutic alternatives with highly specific molecular "probes".
    BJU Int. 2019 Feb 20. doi: 10.1111/bju.14713.
    PubMed     Abstract available

  143. SATHIANATHEN NJ, Philippou YA, Kuntz GM, Konety BR, et al
    Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: A Cochrane Review.
    BJU Int. 2019 Feb 14. doi: 10.1111/bju.14711.
    PubMed     Abstract available

  144. STABILE A, Orczyk C, Hosking-Jervis F, Giganti F, et al
    Medium term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using HIFU for primary localized prostate cancer.
    BJU Int. 2019 Feb 12. doi: 10.1111/bju.14710.
    PubMed     Abstract available

  145. MERRIEL SWD, Hetherington L, Seggie A, Castle JT, et al
    Best practice in Active Surveillance for men with prostate cancer: A Prostate Cancer UK consensus statement.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14707.
    PubMed     Abstract available

  146. GLASS AS, Dall'Era MA
    Use of Multi-Parametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
    BJU Int. 2019 Feb 11. doi: 10.1111/bju.14705.
    PubMed     Abstract available

  147. LIGHT A, Elhage O, Marconi L, Dasgupta P, et al
    Prostate cancer screening: where are we now?
    BJU Int. 2019 Feb 5. doi: 10.1111/bju.14692.
    PubMed     Abstract available

  148. KAM J, Yuminaga Y, Krelle M, Gavin D, et al
    How accurate is multi-parametric MRI for predicting prostate cancer pathology and tumour staging in the real world? - An Australian multi-centre study.
    BJU Int. 2019 Feb 3. doi: 10.1111/bju.14696.
    PubMed     Abstract available

  149. KRIMPHOVE MJ, Fletcher SA, Trinh QD
    Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect real-world practice?
    BJU Int. 2019;123:197-198.

  150. ROSE BS
    Postoperative radiation and hormonal therapy for men with node-positive prostate cancer: a new standard?
    BJU Int. 2019;123:199-200.

  151. TAAFFE DR, Galvao DA, Spry N, Joseph D, et al
    Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    BJU Int. 2019;123:261-269.
    PubMed     Abstract available

  152. KINNEAR N, O'Callaghan M, Hennessey D, Liddell H, et al
    Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2019;123:210-219.
    PubMed     Abstract available

  153. GUPTA M, Patel HD, Schwen ZR, Tran PT, et al
    Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
    BJU Int. 2019;123:252-260.
    PubMed     Abstract available

    January 2019
  154. SIMOPOULOS DN, Sisk AE Jr, Priester A, Felker ER, et al
    Cancer Core Length from Targeted Biopsy: An Index of Prostate Cancer Volume and Pathologic Stage.
    BJU Int. 2019 Jan 29. doi: 10.1111/bju.14691.
    PubMed     Abstract available

  155. ANING JJ, Reilly GS, Fowler S, Challacombe B, et al
    Peri-operative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon reported data.
    BJU Int. 2019 Jan 25. doi: 10.1111/bju.14687.
    PubMed     Abstract available

  156. SIGHINOLFI MC, Sandri M, Torricelli P, Ligabue G, et al
    External validation of a novel side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer: preliminary outcomes on a series diagnosed with mpMRI targeted plus systematic sa
    BJU Int. 2019 Jan 18. doi: 10.1111/bju.14665.
    PubMed     Abstract available

  157. REICHARD CA, Nyame YA, Sundi D, Tosoian J, et al
    Does time from diagnosis to treatment of high or very high risk prostate cancer affect outcome?
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14671.
    PubMed     Abstract available

  158. MA WK, Poon DM, Chan CK, Chan TW, et al
    Consensus statements on the management of clinically localised prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14681.
    PubMed     Abstract available

  159. ROBINSON D, Garmo H, Van Hemelrijck M, Damber JE, et al
    Androgen deprivation therapy for prostate cancer and risk of dementia.
    BJU Int. 2019 Jan 13. doi: 10.1111/bju.14666.
    PubMed     Abstract available

  160. OMLIN A, Gillessen S
    The Advanced Prostate Cancer Consensus on a regional level - what can we learn?
    BJU Int. 2019;123:3-4.

  161. WONG NC, Lam C, Patterson L, Shayegan B, et al
    Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy.
    BJU Int. 2019;123:51-57.
    PubMed     Abstract available

  162. STONIER T, Simson N, Davis J, Challacombe B, et al
    Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) vs standard RARP: it's time for critical appraisal.
    BJU Int. 2019;123:5-7.

  163. DESAI M, Bidair M, Bhojani N, Trainer A, et al
    WATER II (80-150 mL) procedural outcomes.
    BJU Int. 2019;123:106-112.
    PubMed     Abstract available

    December 2018
  164. GUPTA N, Bivalacqua TJ, Han M, Gorin MA, et al
    Evaluating the Impact of Length of Time from Diagnosis to Surgery in Patients with Unfavorable Intermediate to Very High-Risk Clinically Localized Prostate Cancer.
    BJU Int. 2018 Dec 20. doi: 10.1111/bju.14659.
    PubMed     Abstract available

  165. YANG YJ, Kong YY, Li GX, Wang Y, et al
    Phenotypes of Circulating Tumor Cells Predict Time to Castration Resistance in Metastatic Castration-Sensitive Prostate Cancer.
    BJU Int. 2018 Dec 7. doi: 10.1111/bju.14642.
    PubMed     Abstract available

  166. ROCCO B, Sighinolfi MC, Sandri M, Puliatti S, et al
    A novel nomogram for predicting ECE of prostate cancer.
    BJU Int. 2018;122:916-918.

    November 2018
  167. GNANAPRAGASAM V, Barrett T, Massie C, Pacey S, et al
    Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.
    BJU Int. 2018 Nov 30. doi: 10.1111/bju.14637.
    PubMed     Abstract available

  168. CHANDRASEKAR T, Dall'Era MA, Tilki D
    Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer.
    BJU Int. 2018;122:721-722.

    October 2018
  169. ORCZYK C, Villers A, Rusinek H, Lepennec V, et al
    Prostate cancer heterogeneity: texture analysis score based on multiple MRI sequences for detection, stratification and selection of lesions at time of biopsy.
    BJU Int. 2018 Oct 30. doi: 10.1111/bju.14603.
    PubMed     Abstract available

  170. COLLINS A, Sundararajan V, Millar J, Burchell J, et al
    The trajectory of people who die from metastatic prostate cancer: A population-based study.
    BJU Int. 2018 Oct 29. doi: 10.1111/bju.14593.
    PubMed     Abstract available

  171. ONG WL, Yaxley JW, Millar JL
    Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer - time to reverse the declining trend?
    BJU Int. 2018 Oct 19. doi: 10.1111/bju.14487.

  172. VARMA M, Cochlin D, Delahunt B, Kynaston H, et al
    TNM clinical staging of prostate cancer: Issues and solutions.
    BJU Int. 2018 Oct 13. doi: 10.1111/bju.14589.
    PubMed     Abstract available

  173. GIELCHINSKY I, Chang J, Cusick T, Delprado W, et al
    Prostate Cancer in 432 men under the age of 50 years in the Prostate Specific Antigen era - a new outlook.
    BJU Int. 2018 Oct 10. doi: 10.1111/bju.14586.
    PubMed     Abstract available

  174. PINSKY PF, Miller E, Prorok P, Grubb R, et al
    Extended follow-up for prostate cancer incidence and mortality in the PLCO randomized cancer screening trial.
    BJU Int. 2018 Oct 5. doi: 10.1111/bju.14580.
    PubMed     Abstract available

  175. WARNER EW, Yip SM, Chi KN, Wyatt AW, et al
    DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14576.
    PubMed     Abstract available

  176. TORRES-ROMAN JS, Ruiz EF, Martinez-Herrera JF, Mendes Braga SF, et al
    Prostate Cancer Mortality rates in Peru and its geographic regions.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14578.
    PubMed     Abstract available

    September 2018
  177. CAZZANIGA W, Garmo H, Robinson D, Holmberg L, et al
    Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.
    BJU Int. 2018 Sep 25. doi: 10.1111/bju.14563.
    PubMed     Abstract available

  178. KAYE DR, Qi J, Morgan TM, Linsell S, et al
    Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    BJU Int. 2018 Sep 24. doi: 10.1111/bju.14554.
    PubMed     Abstract available

  179. VAN NIEUWENHOVE S, Saussez TP, Thiry S, Trefois P, et al
    Prospective comparison of a fast 1.5T biparametric to the 3.0T multi-parametric ESUR magnetic resonance imaging protocol as triage test for men at risk of prostate cancer.
    BJU Int. 2018 Sep 21. doi: 10.1111/bju.14538.
    PubMed     Abstract available

  180. STEUBER T, Tennstedt P, Macagno A, Athanasiou A, et al
    Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14540.
    PubMed     Abstract available

  181. VAN ROMPAY MI, Nickel JC, Ranganathan G, Kantoff PW, et al
    Impact of 5alpha-Reductase Inhibitors and alpha-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14534.
    PubMed     Abstract available

  182. JAMES ND
    Prognostic and predictive models in hormone-sensitive prostate cancer.
    BJU Int. 2018;122:352-353.

  183. HUGHES SR
    2018: A Spacer Odyssey.
    BJU Int. 2018;122:353-354.

  184. OXLEY J, Bray A, Rowe E
    Could a Mohs technique make NeuroSAFE a viable option?
    BJU Int. 2018;122:358-359.

  185. CHANG KD, Abdel Raheem A, Choi YD, Chung BH, et al
    Retzius-sparing robot-assisted radical prostatectomy using the Revo-i robotic surgical system: surgical technique and results of the first human trial.
    BJU Int. 2018;122:441-448.
    PubMed     Abstract available

  186. KAOUK JH, Sagalovich D, Garisto J
    Robot-assisted transvesical partial prostatectomy using a purpose-built single-port robotic system.
    BJU Int. 2018;122:520-524.
    PubMed     Abstract available

  187. CHANDAK P, Byrne N, Lynch H, Allen C, et al
    Three-dimensional printing in robot-assisted radical prostatectomy - an Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) Phase 2a study.
    BJU Int. 2018;122:360-361.

  188. KADONO Y, Nohara T, Kawaguchi S, Naito R, et al
    Investigating the mechanism underlying urinary continence recovery after radical prostatectomy: effectiveness of a longer urethral stump to prevent urinary incontinence.
    BJU Int. 2018;122:456-462.
    PubMed     Abstract available

    August 2018
  189. WISSING M, Brimo F, Chevalier S, Scarlata E, et al
    Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14512.
    PubMed     Abstract available

  190. SHAH PH, Patel VR, Moreira DM, George AK, et al
    Implementation of Multiparametric Magnetic Resonance Imaging Technology for Evaluation of Patients with Suspicion for Prostate Cancer in the Clinical Practice Setting.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14515.
    PubMed     Abstract available

  191. JUNG JH, Risk MC, Goldfarb R, Reddy B, et al
    Primary cryotherapy for localised or locally advanced prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14519.
    PubMed     Abstract available

  192. FENIOUX C, Louvet C, Charton E, Rozet F, et al
    Switch from Abiraterone + Prednisone to Abiraterone + Dexamethasone at asymptomatic PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14511.
    PubMed     Abstract available

  193. CARLES J, Pichler A, Korunkova H, Tomova A, et al
    Observational, multicenter study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14509.
    PubMed     Abstract available

  194. VAN LEEUWEN PJ, Donswijk M, Nandurkar R, Stricker P, et al
    68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer.
    BJU Int. 2018 Aug 3. doi: 10.1111/bju.14506.
    PubMed     Abstract available

  195. NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: (c) NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.
    BJU Int. 2018;122:173-180.

  196. CULIG Z
    The way towards understanding possible multiple functions of AR V7 in prostate cancer.
    BJU Int. 2018;122:169.

  197. THOMPSON JE, Stricker PD
    MRI improves active surveillance of prostate cancer however biopsy is still crucial.
    BJU Int. 2018;122:E1-E2.

  198. Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia.
    BJU Int. 2018;122 Suppl 2:23-38.

  199. CACCIAMANI G, Medina L, Ashrafi A, Landsberger H, et al
    Transvesical robot-assisted simple prostatectomy with 360 degrees circumferential reconstruction: step-by-step technique.
    BJU Int. 2018;122:344-348.
    PubMed     Abstract available

  200. MAXEINER A, Kittner B, Blobel C, Wiemer L, et al
    Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    BJU Int. 2018;122:211-218.
    PubMed     Abstract available

  201. KNAAPILA J, Kallio H, Hakanen AJ, Syvanen K, et al
    Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study.
    BJU Int. 2018;122:203-210.
    PubMed     Abstract available

  202. HUYNH LM, Osann K, Skarecky D, Ahlering TE, et al
    Predictive modelling of 2-year potency outcomes using a novel 90-day erection fullness scale after robot-assisted radical prostatectomy.
    BJU Int. 2018;122:249-254.
    PubMed     Abstract available

    July 2018
  203. SCAILTEUX LM, Rioux-Leclercq N, Vincendeau S, Balusson F, et al
    Use of 5alpha-reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer: A French population-based study.
    BJU Int. 2018 Jul 19. doi: 10.1111/bju.14495.
    PubMed     Abstract available

  204. CHIONG E, Murphy DG, Akaza H, Buchan NC, et al
    Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    BJU Int. 2018 Jul 18. doi: 10.1111/bju.14489.
    PubMed     Abstract available

  205. PAK S, Park S, Kim M, Go H, et al
    The impact on oncologic outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumor positive to negative.
    BJU Int. 2018 Jul 6. doi: 10.1111/bju.14480.
    PubMed     Abstract available

  206. DAHRAN N, Szewczyk-Bieda M, Vinnicombe S, Fleming S, et al
    Periprostatic Fat Adipokines Expression Correlated with Prostate Cancer Aggressiveness in Men Undergoing Radical Prostatectomy for Clinically Localised Disease.
    BJU Int. 2018 Jul 3. doi: 10.1111/bju.14469.
    PubMed     Abstract available

  207. POPERT R
    Systematic transperineal and magnetic resonance imaging-targeted biopsies: the resolution of uncertainty.
    BJU Int. 2018;122:6-7.

  208. LAVIANA AA, Penson DF
    Multiparametric magnetic resonance imaging (MRI) with targeted fusion biopsy: is the time now?
    BJU Int. 2018;122:1-2.

  209. DE NUNZIO C, Lombardo R, Nacchia A, Tema G, et al
    Repeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer.
    BJU Int. 2018;122:83-88.
    PubMed     Abstract available

    June 2018
  210. STONE NN, Stock RG
    Stage T3b prostate cancer diagnosed with seminal vesicle biopsy and treated by neoadjuvant hormone therapy, permanent brachytherapy and external beam irradiation.
    BJU Int. 2018 Jun 29. doi: 10.1111/bju.14464.
    PubMed     Abstract available

  211. ELLIOTT D, Hamdy FC, Leslie TA, Rosario D, et al
    Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation versus radical prostatectomy for unilateral localised prostate cancer.
    BJU Int. 2018 Jun 11. doi: 10.1111/bju.14432.
    PubMed     Abstract available

  212. KUANG AG, Nickel JC, Andriole GL, Castro-Santamaria R, et al
    Both acute and chronic inflammation are associated with lower perineural invasion in men with prostate cancer on repeat biopsy.
    BJU Int. 2018 Jun 6. doi: 10.1111/bju.14428.
    PubMed     Abstract available

  213. SOOD A, Abdollah F, Menon M
    Robot-assisted radical prostatectomy and a parachute.
    BJU Int. 2018;121:820-821.

    May 2018
  214. OTTI VC, Miller C, Powell RJ, Thomas RM, et al
    The diagnostic accuracy of multiparametric MRI prior to biopsy in the detection of prostate cancer.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14420.
    PubMed     Abstract available

  215. BANCROFT EK, Saya S, Page EC, Myhill K, et al
    The psychosocial impact of undergoing prostate cancer screening for men with BRCA1/2 mutations.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14412.
    PubMed     Abstract available

  216. SZARVAS T, Sevcenco S, Modos O, Keresztes D, et al
    MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14415.
    PubMed     Abstract available

  217. KOVAC E, Vertosick EA, Sjoberg DD, Vickers AJ, et al
    Effects of Pathologic Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in men with Clinical Low-risk Prostate Cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14418.
    PubMed     Abstract available

  218. LOEB S, Taneja S, Walter D, Zweifach S, et al
    Crowd-Funding for Prostate Cancer and Breast Cancer.
    BJU Int. 2018 May 22. doi: 10.1111/bju.14408.
    PubMed     Abstract available

  219. ALI A, Hoyle A, Mistry H, Clarke NW, et al
    The importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    BJU Int. 2018 May 19. doi: 10.1111/bju.14400.
    PubMed     Abstract available

  220. GANDAGLIA G, van den Bergh RCN, Tilki D, Fossati N, et al
    How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14391.
    PubMed     Abstract available

  221. ZHAO J, Sun G, Liao B, Zhang X, et al
    Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone-metastatic prostate cancer.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14398.
    PubMed     Abstract available

  222. ISHIOKA J, Matsuoka Y, Uehara S, Yasuda Y, et al
    Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14397.
    PubMed     Abstract available

  223. HAJILI T, Ohlmann CH, Linxweiler J, Niklas C, et al
    Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14393.
    PubMed     Abstract available

  224. NEWTON RU, Jeffery E, Galvao DA, McIntyre C, et al
    Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen deprivation therapy.
    BJU Int. 2018 May 11. doi: 10.1111/bju.14384.
    PubMed     Abstract available

  225. HOFMAN MS, Murphy DG, Williams SG, Nzenza T, et al
    A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14374.
    PubMed     Abstract available

    Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age?
    BJU Int. 2018;121:676-677.

  227. VENTIMIGLIA E, Briganti A, Montorsi F
    Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications.
    BJU Int. 2018;121:677-678.

  228. REYNOLDS BR, Bulsara C, Zeps N, Codde J, et al
    Exploring pathways towards improving patient experience of robot-assisted radical prostatectomy (RARP): assessing patient satisfaction and attitudes.
    BJU Int. 2018;121 Suppl 3:33-39.
    PubMed     Abstract available

  229. MISCHINGER J, Kaufmann S, Russo GI, Harland N, et al
    Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2018;121:791-798.
    PubMed     Abstract available

  230. MADERTHANER L, Furrer MA, Studer UE, Burkhard FC, et al
    More extended lymph node dissection template at radical prostatectomy detects metastases in the common iliac region and in the fossa of Marcille.
    BJU Int. 2018;121:725-731.
    PubMed     Abstract available

    April 2018
  231. BRIZMOHUN APPAYYA M, Adshead J, Ahmed HU, Allen C, et al
    National Implementation of multi-parametric MRI for prostate cancer detection - Recommendations from a UK consensus meeting.
    BJU Int. 2018 Apr 26. doi: 10.1111/bju.14361.
    PubMed     Abstract available

  232. SCHOOTS IG, Nieboer D, Giganti F, Moore CM, et al
    Is MRI-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
    BJU Int. 2018 Apr 21. doi: 10.1111/bju.14358.
    PubMed     Abstract available

  233. MARTINI A, Gupta A, Lewis SC, Cumarasamy S, et al
    Development and Internal Validation of a Side Specific, Multiparametric MRI-based Nomogram for the Prediction of Extracapsular Extension of Prostate Cancer.
    BJU Int. 2018 Apr 19. doi: 10.1111/bju.14353.
    PubMed     Abstract available

  234. BRYANT RJ, Yang B, Philippou Y, Lam K, et al
    Does the introduction of prostate multiparametric MRI into active surveillance of localised prostate cancer improve patient re-classification?
    BJU Int. 2018 Apr 12. doi: 10.1111/bju.14248.
    PubMed     Abstract available

  235. CASH H, Steiner U, Heidenreich A, Klotz T, et al
    Intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration resistant prostate cancer (CRPC) - a phase III study (PRINCE).
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14239.
    PubMed     Abstract available

  236. LANCEE M, Tikkinen KAO, de Reijke TM, Kataja VV, et al
    Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14237.
    PubMed     Abstract available

  237. EBBINGE M, Berglund A, Varenhorst E, Hedlund PO, et al
    Clinical and Prognostic Significance of Changes in Haemoglobin Level During One Year of Androgen Deprivation Treatment for Hormone-Naive Bone Metastatic Prostate Cancer.
    BJU Int. 2018 Apr 2. doi: 10.1111/bju.14227.
    PubMed     Abstract available

  238. HARMOUCH SS, Berger AJ, Cole AP
    Low rates of bone density testing in prostate cancer survivors on androgen-deprivation therapy: where do we go from here?
    BJU Int. 2018;121:492-493.

  239. KLOTZ L
    Prostate cancer prevention: proof is elusive.
    BJU Int. 2018;121:487-488.

  240. LAING R, Uribe J, Uribe-Lewis S, Money-Kyrle J, et al
    LDR brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    BJU Int. 2018 Apr 1. doi: 10.1111/bju.14223.
    PubMed     Abstract available

  241. BANDINI M, Marchioni M, Pompe RS, Tian Z, et al
    First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy.
    BJU Int. 2018;121:592-599.
    PubMed     Abstract available

    March 2018
  242. VATANDOUST S, Kichenadasse G, O'Callaghan M, Vincent AD, et al
    Localized prostate cancer in elderly men aged 80-89, findings from a population-based registry.
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14228.
    PubMed     Abstract available

  243. ANSMANN L, Winter N, Ernstmann N, Heidenreich A, et al
    Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW).
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14215.
    PubMed     Abstract available

  244. STATTIN P, Sandin F, Loeb S, Robinson D, et al
    Public online reporting from a nationwide population-based clinical prostate cancer register.
    BJU Int. 2018 Mar 25. doi: 10.1111/bju.14213.
    PubMed     Abstract available

  245. CHEN R, Dong X, Gleave M
    Molecular Model for Neuroendocrine Prostate Cancer Progression.
    BJU Int. 2018 Mar 22. doi: 10.1111/bju.14207.
    PubMed     Abstract available

  246. AUBERTIN K, Trinh VQ, Jermyn M, Baksic P, et al
    Mesoscopic characterization of prostate cancer using Raman spectroscopy: Potential for diagnostics and therapeutics.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14199.
    PubMed     Abstract available

  247. RUSSO GI, Bier S, Hennenlotter J, Beger G, et al
    Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14200.
    PubMed     Abstract available

  248. VIDAL AC, Howard LE, de Hoedt A, Kane CJ, et al
    Obese Castration-Resistant Prostate Cancer Patients may be at a lower risk of all-cause mortality: Results from the SEARCH Database.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14193.
    PubMed     Abstract available

  249. CHAO M, Ho H, Chan Y, Tan A, et al
    Prospective analysis of hydrogel spacer for prostate cancer patients undergoing radiotherapy.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14192.
    PubMed     Abstract available

  250. COUTURE F, Tholomier C, Zorn KC
    Prostate cancer biochemical recurrence after salvage radiotherapy: first look into risk stratification and prognosis.
    BJU Int. 2018;121:320-321.

  251. GHANEM S, Namdarian B, Challacombe B
    To drain or not to drain after robot-assisted radical prostatectomy? That is the question.
    BJU Int. 2018;121:321-322.

  252. PALAYAPALAYAM GANAPATHI H, Onol F, Rogers T, Patel V, et al
    Nerve wrapping with biomaterials during radical prostatectomy to improve potency recovery.
    BJU Int. 2018;121:322-323.

  253. SATHIANATHEN NJ, Christidis D, Konety BR, Lawrentschuk NL, et al
    Magnetic resonance imaging cognitive fusion biopsy - is near enough good enough?
    BJU Int. 2018;121:324-326.

  254. PATEL VR, Sandri M, Grasso AAC, De Lorenzis E, et al
    A novel tool for predicting extracapsular extension during graded partial nerve sparing in radical prostatectomy.
    BJU Int. 2018;121:373-382.
    PubMed     Abstract available

  255. CHENAM A, Yuh B, Zhumkhawala A, Ruel N, et al
    Prospective randomised non-inferiority trial of pelvic drain placement vs no pelvic drain placement after robot-assisted radical prostatectomy.
    BJU Int. 2018;121:357-364.
    PubMed     Abstract available

  256. MAI Z, Xiao Y, Yan W, Zhou Y, et al
    Comparison of lesions detected and undetected by template-guided transperineal saturation prostate biopsy.
    BJU Int. 2018;121:415-420.
    PubMed     Abstract available

  257. PORPIGLIA F, Bertolo R, Fiori C, Manfredi M, et al
    Chitosan membranes applied on the prostatic neurovascular bundles after nerve-sparing robot-assisted radical prostatectomy: a phase II study.
    BJU Int. 2018;121:472-478.
    PubMed     Abstract available

    February 2018
  258. NASSAR ZD, Aref AT, Miladinovic D, Mah CY, et al
    Peri-Prostatic Adipose Tissue: The metabolic microenvironment of prostate cancer.
    BJU Int. 2018 Feb 20. doi: 10.1111/bju.14173.
    PubMed     Abstract available

  259. ALTOK M, Babaian K, Achim MF, Achim GC, et al
    Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection.
    BJU Int. 2018 Feb 15. doi: 10.1111/bju.14164.
    PubMed     Abstract available

  260. BOLTON EM, Lynch TH
    Are all gonadotropin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14168.
    PubMed     Abstract available

  261. THURTLE D, Barrett T, Thankappan-Nair V, Koo B, et al
    Progression and treatment rates using an active surveillance protocol incorporating image guided baseline biopsies and multi-parametric MRI monitoring for men with favourable risk prostate cancer.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14166.
    PubMed     Abstract available

    Surgery for oligometastatic prostate cancer: ready for prime time?
    BJU Int. 2018 Feb 12. doi: 10.1111/bju.14038.

  263. WALLIS CJD, Satkunasivam R, Bhindi B
    Selecting patients for prostate cancer treatment: the role of comorbidity.
    BJU Int. 2018;121:164-165.

  264. SOLIGO M, Sharma V, Karnes RJ
    Is it time for a more 'proactive' approach to metastatic prostate cancer?
    BJU Int. 2018;121:167-168.

  265. BARNETT CL, Davenport MS, Montgomery JS, Wei JT, et al
    Cost-Effectiveness of Magnetic Resonance Imaging and Targeted Fusion Biopsy for Early Detection of Prostate Cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14151.
    PubMed     Abstract available

  266. GILBERT DC, Duong T, Sydes M, Bara A, et al
    Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14153.
    PubMed     Abstract available

  267. SONPAVDE G, Huang A, Wang L, Baser O, et al
    Taxane chemotherapy versus anti-androgen agents as first-line therapy for metastatic castration-resistant prostate cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14152.
    PubMed     Abstract available

  268. HEIDENREICH A, Pfister D
    Even 'low-dose' cabazitaxel requires careful and meticulous patient selection.
    BJU Int. 2018;121:163-164.

  269. KENIGSBERG AP, Tamada T, Rosenkrantz AB, Llukani E, et al
    Multiparametric magnetic resonance imaging identifies significant apical prostate cancers.
    BJU Int. 2018;121:239-243.
    PubMed     Abstract available

  270. AUFFENBERG GB, Qi J, Gao Y, Miller DC, et al
    Evaluation of a needle disinfectant technique to reduce infection-related hospitalisation after transrectal prostate biopsy.
    BJU Int. 2018;121:232-238.
    PubMed     Abstract available

    January 2018
  271. RUTLEDGE AB, McLeod N, Mehan N, Regan TW, et al
    A clinician-centred program for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14144.
    PubMed     Abstract available

  272. ABDEL-RAHMAN O, Cheung WY
    External Validation Of The Prostascore Model Among Metastatic Hormone-Sensitive Prostate Cancer Patients Recruited In The CHAARTED Study.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14138.
    PubMed     Abstract available

  273. LAZAREV S, Thompson MR, Stone NN, Stock RG, et al
    Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10 Years of Follow-Up.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14122.
    PubMed     Abstract available

  274. SCHLUSSEL MARKOVIC E, Buckstein M, Stone NN, Stock RG, et al
    Outcomes and Toxicities in Intermediate-Risk Prostate Cancer Patients Treated with Brachytherapy Alone or Brachytherapy and Supplemental External Beam Radiation Therapy.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14128.
    PubMed     Abstract available

  275. FLETCHER SA, Berg S, Trinh QD
    The new frontier of prostate biopsy: determining the role of image-guidance in moving the needle.
    BJU Int. 2018;121:4-5.

  276. STONE N
    Low dose rate prostate brachytherapy in younger men.
    BJU Int. 2018;121:2.

  277. BORKOWETZ A, Hadaschik B, Platzek I, Toma M, et al
    Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naive patients.
    BJU Int. 2018;121:53-60.
    PubMed     Abstract available

  278. SHIN T, Smyth TB, Ukimura O, Ahmadi N, et al
    Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image-fusion targeted biopsy of the prostate.
    BJU Int. 2018;121:77-83.
    PubMed     Abstract available

  279. SU J, Zhu Q, Yuan L, Zhang Y, et al
    Transumbilical laparoendoscopic single-site radical prostatectomy and cystectomy with the aid of a transurethral port: a feasibility study.
    BJU Int. 2018;121:111-118.
    PubMed     Abstract available

    December 2017
  280. NANTON V, Appleton R, Loew J, Ahmed N, et al
    Men don't talk about their health, but will they CHAT? The potential of online holistic needs assessment in prostate cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14114.
    PubMed     Abstract available

  281. BRUINSMA SM, Zhang L, Roobol MJ, Bangma CH, et al
    The Movember Foundation's GAP3 cohort: A profile of the largest global prostate cancer active surveillance database to date.
    BJU Int. 2017 Dec 15. doi: 10.1111/bju.14106.
    PubMed     Abstract available

  282. VOSS J, Pal R, Ahmed S, Hannah M, et al
    Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    BJU Int. 2017 Dec 14. doi: 10.1111/bju.14100.
    PubMed     Abstract available

  283. DRUSKIN SC, Tosoian JJ, Young A, Collica S, et al
    Incorporating Prostate Health Index Density, MRI, and Prior Negative Biopsy Status to Improve the Detection of Clinically Significant Prostate Cancer.
    BJU Int. 2017 Dec 12. doi: 10.1111/bju.14098.
    PubMed     Abstract available

  284. POON DM, Chan CK, Chan TW, Cheung FY, et al
    Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    BJU Int. 2017 Dec 6. doi: 10.1111/bju.14091.
    PubMed     Abstract available

  285. PORPIGLIA F, De Luca S
    Prostate cancer biomarkers: new scenarios in the multi-parametric magnetic resonance imaging era.
    BJU Int. 2017;120:745-746.

  286. BULTIJNCK R, Van de Caveye I, Rammant E, Everaert S, et al
    Clinical Pathway improves Implementation of Evidence-based Strategies for the management of Androgen Deprivation Therapy-induced side effects in Prostate Cancer Patients.
    BJU Int. 2017 Dec 1. doi: 10.1111/bju.14086.
    PubMed     Abstract available

  287. BJURLIN MA, Taneja SS
    Novel risk stratification nomograms for counseling patients on the need for prostate biopsy.
    BJU Int. 2017;120:746-747.

    NICE guidance and the BJUI.
    BJU Int. 2017;120:743.

    November 2017
  289. KIRK PS, Borza T, Shahinian VB, Caram MEV, et al
    The implications of baseline bone health assessment at initiation of androgen deprivation therapy for prostate cancer.
    BJU Int. 2017 Nov 10. doi: 10.1111/bju.14075.
    PubMed     Abstract available

  290. SIRIWARDANA A, Thompson J, van Leeuwen PJ, Doig S, et al
    Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
    BJU Int. 2017;120:673-681.
    PubMed     Abstract available

  291. BOEHM K, Leyh-Bannurah SR, Rosenbaum C, Brandi LS, et al
    Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.
    BJU Int. 2017;120:666-672.
    PubMed     Abstract available

  292. HANSEN NL, Kesch C, Barrett T, Koo B, et al
    Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
    BJU Int. 2017;120:631-638.
    PubMed     Abstract available

  293. YAXLEY AJ, Yaxley JW, Thangasamy IA, Ballard E, et al
    Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    BJU Int. 2017;120 Suppl 3:43-50.
    PubMed     Abstract available

  294. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    PubMed     Abstract available

  295. LOEB S
    Educational intervention in prostate cancer.
    BJU Int. 2017;120.

  296. CHALFIN HJ, Pienta KJ, Gorin MA
    Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.
    BJU Int. 2017;120.

    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.

    Central pathology review of radical prostatectomy specimens does make a difference not only with grade.
    BJU Int. 2017;120.

    October 2017
  299. GANDAGLIA G, Zaffuto E, Fossati N, Bandini M, et al
    Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14066.
    PubMed     Abstract available

  300. ILIC D, Evans SM, Allan CA, Jung JH, et al
    Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer: a Cochrane systematic review.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14062.
    PubMed     Abstract available

  301. HANSEN NL, Barrett T, Kesch C, Pepdjonovic L, et al
    Multicentre evaluation of Magnetic Resonance Imaging supported transperineal prostate biopsy in biopsy-naive men with suspicion of prostate cancer.
    BJU Int. 2017 Oct 11. doi: 10.1111/bju.14049.
    PubMed     Abstract available

  302. KLAASSEN Z, Murphy DG
    STAMPEDE-ing Towards Androgen Biosynthesis Inhibition for Treatment of High-Risk Hormone-Naive Prostate Cancer: Changing the LATITUDE.
    BJU Int. 2017 Oct 9. doi: 10.1111/bju.14050.
    PubMed     Abstract available

  303. FRADET V, Toren P, Nguile-Makao M, Lodde M, et al
    Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5alpha-reductase inhibitors.
    BJU Int. 2017 Oct 3. doi: 10.1111/bju.14041.
    PubMed     Abstract available

    Anomalous observation with regard to prostate cancer in cancer research.
    BJU Int. 2017;120:456-457.

  305. ALBERTS AR, Roobol MJ, Drost FH, van Leenders GJ, et al
    Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    BJU Int. 2017;120:511-519.
    PubMed     Abstract available

  306. LLUKANI E, Lepor H
    Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.
    BJU Int. 2017;120:505-510.
    PubMed     Abstract available

  307. ZHAO S, Xia M, Tang J, Yan Y, et al
    Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study.
    BJU Int. 2017;120:482-489.
    PubMed     Abstract available

  308. LOEB S, Stork B, Gold HT, Stout NK, et al
    Tweet this: how advocacy for breast and prostate cancers stacks up on social media.
    BJU Int. 2017;120:461-463.

    September 2017
  309. VAN STAM MA, van der Poel HG, van der Voort van Zyp JRN, Tillier CN, et al
    The accuracy of patients' perceptions of the risks associated with localized prostate cancer treatments.
    BJU Int. 2017 Sep 28. doi: 10.1111/bju.14034.
    PubMed     Abstract available

  310. BLANCHARD P, Davis JW, Frank SJ, Kim J, et al
    Quality of life following brachytherapy or bilateral nerve sparing robotic prostatectomy for prostate cancer: a prospective cohort.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14021.
    PubMed     Abstract available

  311. RULACH R, McKay S, Neilson S, White L, et al
    Real World Uptake, Safety Profile and Outcomes of Docetaxel in Newly Diagnosed Metastatic Prostate Cancer.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14025.
    PubMed     Abstract available

  312. BOSCO C, Wong C, Garmo H, Crawley D, et al
    Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14023.
    PubMed     Abstract available

  313. MARRA G, Dalmasso E, Angello M, Munegato S, et al
    Prostate Cancer Treatment in Renal Transplant Recipients: A Systematic Review.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14018.
    PubMed     Abstract available

  314. POON Y, Pechlivanoglou P, Alibhai SMH, Naimark D, et al
    Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen Deprivation Therapy to Reduce Risk of Fragility Fractures.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14015.
    PubMed     Abstract available

  315. TAAFFE DR, Buffart LM, Newton RU, Spry N, et al
    Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14008.
    PubMed     Abstract available

  316. LAWRENTSCHUK N, Corfield JM, Scott A
    Is choline-based PET imaging still relevant in recurrent prostate cancer?
    BJU Int. 2017;120:303-304.

  317. STEURER S, Rico SD, Simon R, Minner S, et al
    High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.
    BJU Int. 2017;120:365-376.
    PubMed     Abstract available

  318. JACKSON WC, Desai NB, Abugharib AE, Tumati V, et al
    Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
    BJU Int. 2017;120:351-357.
    PubMed     Abstract available

  319. KIM PJ, Park JY, Kim HG, Cho YM, et al
    Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma.
    BJU Int. 2017;120:343-350.
    PubMed     Abstract available

  320. SUARDI N, Montorsi F
    Salvage lymph node dissection: if yes, robotics?
    BJU Int. 2017;120:304-305.

  321. FICARRA V, Novara G, Dasgupta P
    Robot-assisted vs open radical prostatectomy: the day after.
    BJU Int. 2017;120:308-309.

    August 2017
  322. SCHELTEMA MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, et al
    Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13991.
    PubMed     Abstract available

  323. JANG WS, Kim MS, Jeong WS, Chang KD, et al
    Does robot-assisted radical prostatectomy benefit prostate cancer patients with bone oligometastases?
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13992.
    PubMed     Abstract available

  324. THOMPSON A, Beresford MJ, Sarmah P, Jefferies ER, et al
    Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post STAMPEDE world.
    BJU Int. 2017 Aug 19. doi: 10.1111/bju.13990.
    PubMed     Abstract available

  325. VAN DEN BOS W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, et al
    Focal irreversible electroporation as primary treatment for localized prostate cancer.
    BJU Int. 2017 Aug 10. doi: 10.1111/bju.13983.
    PubMed     Abstract available

  326. THALMANN GN, Nguyen DP
    Sentinel nodes in prostate cancer- are we chasing a ghost?
    BJU Int. 2017;120:161-162.

  327. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: (c) NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int. 2017;120:168-184.

  328. GORIN MA, Pomper MG, Pienta KJ, Rowe SP, et al
    Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.
    BJU Int. 2017;120:160-161.

  329. PAVLOVICH CP, Rocco B, Druskin SC, Davis JW, et al
    Urinary continence recovery after radical prostatectomy - anatomical/reconstructive and nerve-sparing techniques to improve outcomes.
    BJU Int. 2017;120:185-196.
    PubMed     Abstract available

  330. KADONO Y, Machioka K, Nakashima K, Iijima M, et al
    Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism.
    BJU Int. 2017;120:293-299.
    PubMed     Abstract available

  331. SUJENTHIRAN A, Charman SC, Parry M, Nossiter J, et al
    Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data.
    BJU Int. 2017;120:219-225.
    PubMed     Abstract available

  332. Abstracts of the 18th Asia-Pacific Prostate Cancer Conference 2017, Australia, 30 August-02 September 2017.
    BJU Int. 2017;120 Suppl 1:5-23.

  333. MCGRATH S, Christidis D, Clarebrough E, Ingle R, et al
    Transperineal prostate biopsy - tips for analgesia.
    BJU Int. 2017;120:164-167.

    July 2017
  334. ONG WL, Foroudi F, Evans S, Millar J, et al
    Large institutional variations in androgen deprivation therapy utilization with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    BJU Int. 2017 Jul 27. doi: 10.1111/bju.13969.
    PubMed     Abstract available

  335. BASOURAKOS SP, Davis JW, Chapin BF, Ward JF, et al
    Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13963.
    PubMed     Abstract available

  336. DESS RT, Hartman HE, Aghdam N, Jackson WC, et al
    Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13962.
    PubMed     Abstract available

  337. LANGLEY SEM, Soares R, Uribe J, Uribe-Lewis S, et al
    Long-term oncological outcomes and toxicity in 597 men </=60 years of age at time of low dose rate brachytherapy for localised prostate cancer.
    BJU Int. 2017 Jul 3. doi: 10.1111/bju.13946.
    PubMed     Abstract available

  338. BASOURAKOS SP, Hoffman K, Kim J
    Active surveillance in prostate cancer: new efforts, new voices, new hope.
    BJU Int. 2017;120:4-5.

  339. SAYYID R, Perlis N, Ahmad A, Evans A, et al
    Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension.
    BJU Int. 2017;120:76-82.
    PubMed     Abstract available

  340. MOSCHINI M, Sharma V, Gandaglia G, Dell'Oglio P, et al
    Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.
    BJU Int. 2017;120:69-75.
    PubMed     Abstract available

  341. MAMAWALA MM, Rao K, Landis P, Epstein JI, et al
    Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.
    BJU Int. 2017;120:25-31.
    PubMed     Abstract available

    June 2017
  342. DE BRUYCKER A, Lambert B, Claeys T, Delrue L, et al
    Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    BJU Int. 2017 Jun 24. doi: 10.1111/bju.13938.
    PubMed     Abstract available

    Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13925.
    PubMed     Abstract available

  344. TUMATI V, Jackson WC, Abugharib AE, Raj G, et al
    Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13926.
    PubMed     Abstract available

  345. VILLERS A, Flamand V, Arquimedes RC, Puech P, et al
    Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide.
    BJU Int. 2017;119:968-974.
    PubMed     Abstract available

  346. DIOLOMBI ML, Epstein JI
    Metastatic potential to regional lymph nodes with Gleason score </=7, including tertiary pattern 5, at radical prostatectomy.
    BJU Int. 2017;119:872-878.
    PubMed     Abstract available

  347. CAVALLO JA, Tewari AK
    Somatic-autonomic neurorrhaphy for erectile function restoration after radical prostatectomy.
    BJU Int. 2017;119:816-818.

    May 2017
  348. HEDDEN L, Wassersug R, Mahovlich S, Pollock P, et al
    Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.
    BJU Int. 2017 May 17. doi: 10.1111/bju.13885.
    PubMed     Abstract available

  349. CHIU PKF, Alberts AR, Venderbos LDF, Bangma CH, et al
    Additional benefit of using a risk based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2017 May 12. doi: 10.1111/bju.13913.
    PubMed     Abstract available

  350. TOSOIAN JT, Chappidi MR, Bishoff JT, Freedland SJ, et al
    Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13911.
    PubMed     Abstract available

  351. GREIMAN AK, Rosoff JS, Prasad SM
    Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13875.
    PubMed     Abstract available

  352. ZUMSTEG ZS, Zelefsky MJ, Woo KM, Spratt DE, et al
    Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer.
    BJU Int. 2017 May 2. doi: 10.1111/bju.13903.
    PubMed     Abstract available

  353. GANDAGLIA G, Fossati N, Dell'Oglio P, Montorsi F, et al
    Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?
    BJU Int. 2017;119:652-653.

  354. TOSOIAN JJ, Chappidi M, Feng Z, Humphreys EB, et al
    Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    BJU Int. 2017;119:676-683.
    PubMed     Abstract available

    Reliability of negative multiparametric MRI of the prostate: can we avoid the biopsy? Not yet!
    BJU Int. 2017;119:E9-E10.

    April 2017
  356. PROTOPAPA E, van der Meulen J, Moore CM, Smith SC, et al
    Patient Reported Outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13896.
    PubMed     Abstract available

  357. PARSONS JK, Pierce JP, Mohler J, Paskett E, et al
    The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13890.
    PubMed     Abstract available

  358. CHIEN GW, Slezak JM, Harrison TN, Jung H, et al
    Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population.
    BJU Int. 2017 Apr 19. doi: 10.1111/bju.13843.
    PubMed     Abstract available

  359. CRAWLEY D, Garmo H, Rudman S, Stattin P, et al
    Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer.
    BJU Int. 2017 Apr 18. doi: 10.1111/bju.13880.
    PubMed     Abstract available

  360. VIOLET JA, Hofman MS
    Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
    BJU Int. 2017 Apr 5. doi: 10.1111/bju.13871.
    PubMed     Abstract available

    An end to the phenomenon of 'upgrading' in early prostate cancer?
    BJU Int. 2017;119:506-507.

  362. BAUER RM, Grabbert MT, Klehr B, Gebhartl P, et al
    36-month data for the AdVance XP(R) male sling: results of a prospective multicentre study.
    BJU Int. 2017;119:626-630.
    PubMed     Abstract available

  363. DAVIS JW, MacLennan G
    The BJUI's clinical trials initiative.
    BJU Int. 2017;119:503.

    March 2017
  364. TELANG JM, Lane BR, Cher ML, Miller DC, et al
    Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13862.
    PubMed     Abstract available

  365. DIJKSTRA S, Govers TM, Hendriks RJ, Schalken JA, et al
    Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13861.
    PubMed     Abstract available

  366. GROGAN J, Gupta R, Mahon KL, Stricker PD, et al
    Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in radical prostatectomy patients with long-term follow up.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13857.
    PubMed     Abstract available

  367. HOWARD LE, Moreira D, De Hoedt A, Aronson WJ, et al
    Cut-points for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856.
    PubMed     Abstract available

  368. CLEMENT-ZHAO A, Auvray M, Aboudagga H, Blanc-Durand F, et al
    Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13855.
    PubMed     Abstract available

  369. MACLENNAN S, Williamson PR, Bekema H, Campbell M, et al
    A core outcome set for localised prostate cancer effectiveness trials.
    BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854.
    PubMed     Abstract available

  370. KANDASWAMY GV, Bennett A, Narahari K, Hughes O, et al
    Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate risk localised prostate cancer - results from a large contemporaneous cohort.
    BJU Int. 2017 Mar 20. doi: 10.1111/bju.13850.
    PubMed     Abstract available

  371. BALL MW, Harris KT, Schwen ZR, Mullins JK, et al
    Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series.
    BJU Int. 2017;119:444-448.
    PubMed     Abstract available

    Rethinking cancer surveillance with shared-care models and survivorship plans: the time is now!
    BJU Int. 2017;119:360-361.

    February 2017
  373. FICARRA V, Crestani A, Rossanese M, Palumbo V, et al
    Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy.
    BJU Int. 2017;119:245-253.
    PubMed     Abstract available

  374. MATHIEU R, Lucca I, Vartolomei MD, Mbeutcha A, et al
    Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
    BJU Int. 2017;119:234-238.
    PubMed     Abstract available

  375. WASHINO S, Okochi T, Saito K, Konishi T, et al
    Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients.
    BJU Int. 2017;119:225-233.
    PubMed     Abstract available

    January 2017
  376. SANTOK GD, Abdel Raheem A, Kim LH, Chang K, et al
    Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size.
    BJU Int. 2017;119:135-141.
    PubMed     Abstract available

  377. ZARGAR H, van den Bergh R, Moon D, Lawrentschuk N, et al
    The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    BJU Int. 2017;119:110-115.
    PubMed     Abstract available

  378. DANNEMAN D, Drevin L, Delahunt B, Samaratunga H, et al
    Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    BJU Int. 2017;119:50-56.
    PubMed     Abstract available

  379. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    BJU Int. 2017;119:57-66.
    PubMed     Abstract available

  380. TOSOIAN JJ, Epstein JI
    Prognostic value of prostate biopsy grade: forever a product of sampling.
    BJU Int. 2017;119:5-7.

  381. PERERA M, Katelaris N, Murphy DG, McGrath S, et al
    Prostate Imaging Reporting and Data System score of four or more: active surveillance no more.
    BJU Int. 2017;119:9-12.

    October 2016
  382. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Abstract available

  383. DEVECI S, Gotto GT, Alex B, O'Brien K, et al
    A survey of patient expectations regarding sexual function following radical prostatectomy.
    BJU Int. 2016;118:641-5.
    PubMed     Abstract available

  384. WYSOCK JS, Mendhiratta N, Zattoni F, Meng X, et al
    Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
    BJU Int. 2016;118:515-20.
    PubMed     Abstract available

  385. MURRAY NP, Aedo S, Reyes E, Orellana N, et al
    Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    BJU Int. 2016;118:556-62.
    PubMed     Abstract available

    June 2016
  386. ANDERSON CB, Tin AL, Sjoberg DD, Mulhall JP, et al
    Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.
    BJU Int. 2016;117.
    PubMed     Abstract available

  387. DE NUNZIO C, Presicce F, Lombardo R, Cancrini F, et al
    Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis.
    BJU Int. 2016;117.
    PubMed     Abstract available

  388. DINH KT, Mahal BA, Ziehr DR, Muralidhar V, et al
    Risk of prostate cancer mortality in men with a history of prior cancer.
    BJU Int. 2016;117.
    PubMed     Abstract available

  389. WATSON E, Shinkins B, Frith E, Neal D, et al
    Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    BJU Int. 2016;117.
    PubMed     Abstract available

    June 2015
  390. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Abstract available

    May 2015
  391. CARLSSON S, Drevin L, Loeb S, Widmark A, et al
    Population-based study of long-term functional outcomes after prostate cancer treatment.
    BJU Int. 2015 May 8. doi: 10.1111/bju.13179.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.